Results 131 to 140 of about 17,592 (206)

Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review. [PDF]

Oncol Res
Zhong G, Yang T, Lin S, Zhong M.
europepmc   +1 more source

ISEV2026 Abstract Book

Journal of Extracellular Vesicles, Volume 15, Issue S1, June 2026.
wiley   +1 more source

Pseudo-senescence induced by palbociclib does not sensitise pleural mesothelioma cells to combinations with senolytics. [PDF]

Cell Death Dis
Sreeram I, Plans-Marin S, Cruz-Rodríguez M, Aliagas E, Palau-Gallinat D, Muñoz-Pinedo C, Nadal E.   +6 more
europepmc   +1 more source

Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancer. [PDF]

Oncologist
Brufsky A, Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen A, Estevez M, Cottu P, Thill M, Curigliano G, Rugo HS.   +11 more
europepmc   +1 more source

CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers. [PDF]

Front Immunol
Cui J, Zhang Y, Wu Y, Zhang G, Lan J, Wang Y.   +5 more
europepmc   +1 more source

Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy. [PDF]

Front Med (Lausanne)
Peng X, Chang W.
europepmc   +1 more source

Real-World Data on the Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer. [PDF]

World J Oncol
Savvidou Α, Constantinidou A, Zacharia L, Michailidou K, Zanti Μ, Kitiri S, Marcou Y, Konstantinou I, Kakouri E, Galazi M, Petrou C.   +10 more
europepmc   +1 more source

CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment. [PDF]

Hemasphere
Ringhofer B, Polzer W, Prchal-Murphy M, Doma E, Kollmann S, Gamper E, Kendler J, Maw BS, Zebedin-Brandl E, Li J, Green AR, Krauth MT, Hadzijusufovic E, Ivanov D, Valent P, Hoermann G, Klampfl T, Sexl V, Kollmann K.   +18 more
europepmc   +1 more source

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma. [PDF]

J Immunother Cancer
Rosenbaum E, Seier K, Gularte-Mérida R, Seffar E, Dickson MA, Avutu V, Banks LB, Chan JE, Chi P, Gounder MM, Kelly CM, Keohan ML, Maki RG, Movva S, Reed D, Desir R, Biniakewitz M, Cho JM, Duchemin M, Erinjeri JP, Lefkowitz RA, Koff A, Singer S, Tap W, Qin LX, D'Angelo S.   +25 more
europepmc   +1 more source

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer. [PDF]

ESMO Open
Im SA, Kalinsky K, Jhaveri KL, Loibl S, Turner N, Saura C, Schmid P, Loi S, Hamilton E, Karadurmus N, Wang S, Awan AA, Ciruelos EM, Chung CF, Thanopoulou E, Shankar N, Lim S, Jin Y, Song C, Juric D.   +19 more
europepmc   +1 more source